Sarcomas are heterogeneous and clinically challenging soft tissue and bone cancers.
Although constituting only 1% of all human malignancies, sarcomas represent the second …

Covering: up to 2020 The National Cancer Institute of the United States (NCI) has initiated a
Cancer Moonshot program entitled the NCI Program for Natural Product Discovery. As part …

Aromatic polyketides have attractive biological activities and pharmacological properties.
Different from other polyketides, aromatic polyketides are characterized by their polycyclic …

While promising, immunotherapy has yet to be fully unlocked for the preponderance of
cancers where conventional chemoradiation reigns. This remains particularly evident in …

Efforts to identify and target glioblastoma (GBM) drivers have primarily focused on receptor
tyrosine kinases (RTKs). Clinical benefits, however, have been elusive. Here, we identify an …

Sarcomas represent a distinct group of rare malignant tumors with high heterogeneity.
Limited options with clinical efficacy for the metastatic or local advanced sarcoma existed …

Purpose In a preclinical drug screen, mithramycin was identified as a potent inhibitor of the
Ewing sarcoma EWS–FLI1 transcription factor. We conducted a phase I/II trial to determine …

HOXA9 (Homeobox A9) is a homeotic transcription factor known for more than two decades
to be associated with leukemia. The expression of HOXA9 homeoprotein is associated with …

There is a great need to develop novel approaches to target oncogenic transcription factors
with small molecules. Ewing sarcoma is emblematic of this need, as it depends on the …

Mithramycin A is an antitumor compound used for treatment of several types of cancer
including chronic and acute myeloid leukemia, testicular carcinoma, hypercalcemia and …